Bionano Q1 revenue $6.5M, down 26% YoY; FY2025 guidance $26-30M

Bionano Genomics, Inc.

2025-Q1 EPS reported -$1.15 revenue$6,457,000

Q1 revenue $6.5M vs $8.8M YoY, down 26%; GAAP gross margin improved to 46% from 32%.
Flowcell sales 6,994 units (-15% YoY); to routine customers up 1% after adjusting for new adds.
GAAP operating expense $11.4M, down 66% YoY from cost cuts and restructuring.
Cash, equivalents and investments $29.2M; cash runway extended into Q1 2026.
FY2025 revenue guidance updated to $26-30M; Q2 revenue expected $6.3-6.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.